Trial Profile
Daclatasvir, Simeprevir and Ribavirin as a new IFN-free triple regimen for HCV recurrence after liver transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2015
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 12 Oct 2015 New trial record